Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Leases: 2019-2024

Historic Operating Leases for Amphastar Pharmaceuticals (AMPH) over the last 6 years, with Dec 2024 value amounting to $41.9 million.

  • Amphastar Pharmaceuticals' Operating Leases rose 36.28% to $39.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.4 million, marking a year-over-year increase of 36.28%. This contributed to the annual value of $41.9 million for FY2024, which is 40.91% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Operating Leases stood at $41.9 million for FY2024, which was up 40.91% from $29.7 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Operating Leases registered a high of $41.9 million during FY2024, and its lowest value of $17.5 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Operating Leases had a median value of $29.7 million in 2023 and averaged $31.8 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Operating Leases skyrocketed by 41.45% in 2021 and then declined by 4.08% in 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Leases (Yearly) stood at $17.5 million in 2020, then spiked by 41.45% to $24.7 million in 2021, then declined by 4.08% to $23.7 million in 2022, then increased by 25.44% to $29.7 million in 2023, then skyrocketed by 40.91% to $41.9 million in 2024.